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ABSTRACT 
Osimertinib Mesylate is used for a treatment of non small cell lung cancer (NSCLC). Whereas only few simple, precise and accurate 
spectrophotometric methods were developed for the determination of Osimertinib Mesylate (tagrisso) in pharmaceutical dosage forms. The 
absorption maxima was found to be at 267 nm in method A (0.1N HCl) and shows linearity over the concentration range of 0.002-0.02 µg/mL 
with regression equation y=0.4323x + 0.0104 (r2 = 0.9992). In Method B (Sodium acetate buffer, pH 4.5) the drug obeys Beer Lambert’s law 
(λmax267nm) in the concentration range of 0.002-0.02 µg/mL with regression equation y=0.484x-0.017(r2= 0.9992). In Method C (phosphate  
buffer, pH 7.2) the drug obeys Beer Lambert’s law (λmax267nm) in the concentration range of 0.002-0.02 µg/mL with regression equation 
y=0.2949x+0.0108(r2= 0.9992) In Method D (Methanol ) the drug obeys Beer Lambert’s law (λmax267nm) in the concentration range of 0.002-
0.02 µg/mL with regression equation y=0.6323x+0.003 (r2= 0.999). 1st derivative spectrophotometric method (E, F, G and H) were developed 
in 0.1NHCl and Sodium acetate pH 4.5 and phosphate buffer pH 7.2 and methanol in which Osimertinib Mesylate obeys Beer Lambert’s law 
0.002-0.02 µg/mL and 0.002-0.02 µg/mL and 0.002-0.02 µg/mL and 0.002-0.02 µg/mL with regression equations y=0.0259x + 0.0008 and 
y=0.0137x - 0.0005 and y=0.0097x-0.0008 and y=0.0087-0.0007 respectively. The proposed spectrophotometric method was validated as per 
the ICH guidelines and can be applied for the determination of Osimertinib Mesylate in pharmaceutical formulations.  Osimertinib Mesylate, 
Derivative spectroscopy, Spectrophometry, Validation, Tagrisso. 
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1. INTRODUCTION  
Osimertinib Mesylate (recently known as mereletinib; 
exchange name Tagrisso) is a drug used to treat non little cell 
lung carcinomas with an explicit change. It is a third-age 
epidermal development factor receptor tyrosine kinase 
inhibitor. Created by astrazeneca, the prescription was 
affirmed as a malignancy treatment in 2017 by both the 
nourishment and medication organization and the European 
commission. 
  Osimertinib Mesylate is a little atom tyrosine kinase 
receptor inhibitor and antineoplastic operator that is utilized 
in the treatment of chose types of cutting edge non-little cell 
lung malignant growth (NSCLC). Osimertinib Mesylate is 
related with a moderate rate of serum aminotransferase 
rises amid treatment and uncommon cases of clinically 
obvious intense liver damage.  
 
Figure 1: Structure of Osimertinib Mesylate 
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2. MATERIALS AND METHODS 
2.1 Instrumentation 
A double beam UV-VIS spectrophotometer (UV-1800, 
Shimadzu, Japan) connected to a computer loaded with 
spectra manager software UV Probe was employed with a 
spectral bandwidth of 1nm and wavelength accuracy of ± 0.3 
nm with a pair of 10 mm path length matched quartz cells. 
All weights were taken on the electronic balance (Shimadzu). 
For scanning, the wavelength range selected was 400nm to 
200nm with medium scanning speed.  
2.2 Chemicals and reagents 
HPLC grade Methanol (Merck), glacial acetic acid (Merck), 
sodium acetate trihydrate (Merck), Hydrochloric acid 
(Rankem) potassium Di-hydrogen phosphate (Merck),  and 
sodium hydroxide (Merck) was used. Osimertinib Mesylate, 
obtained as a gift sample from 
2.3 Preparation of 0.1N HCl  
 Add 4.25mL of 35% Conc. Hydrochloric acid (Hcl) was 
added to the 500mL volumetric flask containing 450mL of 
distilled water or de-ionised water and mixed well. The 
volume was then made up to 500mL of water.  
2.4 Preparation of Sodium Acetate Buffer (pH 4.5) 
 Weigh accurately Sodium acetate trihydrate (1.48 gm) in a 
500ml volumetric flask containing 500ml distilled  water and 
mixed well, then 1.7mL glacial acetic acid (GAA) was added 
to it and the pH adjusted to 4.5 with respectively to  glacial 
acetic acid. 
2.5 Preparation of phosphate buffer pH 7.2 
6.8grams of potassium Di-hydrogen phosphate and 1.4grams 
of sodium hydroxide were weighed accurately and was 
added in a 1000ml volumetric flask containing 900ml 
deionized water and mixed well. The volume was made up 
with water to 1000ml.  
 2.6 Preparation of stock solution 
The standard solution of Osimertinib Mesylate was prepared 
by dissolving accurately about 10 mg of the Osimertinib 
Mesylate with methanol in a 10 ml volumetric flask.  
The stock solution was further diluted with 0.1N HCl and pH 
4.5 sodium acetate buffer for method A (0.002-0.02µg/mL) 
and method B (0.002-0.02µg/mL) and pH 7.2 phosphate 
buffer for method C (0.002-0.02µg/mL) and methanol buffer 
for method D (0.002-0.02µg/mL) respectively as per the 
requirement. 
2.7 Procedure for preparation of the calibration curve 
 The drug solutions were scanned (200-400 nm) against the 
reagent blank (0.1N HCl for method A and sodium acetate 
buffer pH 4.5 for method B and  phosphate buffer pH 6.8 for 
method C and  phosphate buffer pH 7.2 for method D ) and 
the absorption spectra were recorded. The absorption 
maximum (λmax) was observed at 267 nm for method A, B, C 
and D. The absorption spectra so obtained were converted in 
to first derivative spectra by the inbuilt software of the 
instrument and the resulting spectrum shows both maxima 
and minima and therefore the magnitude of the amplitude 
was recorded against concentration for method E, F, G and H. 
Calibration curves were constructed by taking the 
concentration of the drug solutions on the x-axis and the 
corresponding absorbance values on the y-axis. 
 
2.8 The assay procedure for the marketed formulations 
(Tablets) 
 Osimertinib Mesylate Mesyalate is available with brand 
name Tagrisso (0.5 mg and 1mg of the drug per tablet; 
America Pharmaceuticals Inc.) were purchased from the 
local market. Twenty tablets average weight was calculated 
and crushed into fine powder. Osimertinib Mesylate 
equivalent to 25 mg was weighed, extracted with methanol 
by sonication for 40 minutes with intermittent shaking and 
makeup to volume with methanol in 250 ml volumetric flask 
(0.1mg/mL) and centrifuged at 4000rpm for 10 minutes to 
collect the supernatant for further dilutions. The dilutions 
were made from this stock as per the requirement for 
method A, B, C and Dand the percentage recovery was 
calculated. 
2.9 Precision and Accuracy 
The precision and accuracy studies as per the ICH guidelines 
were performed. The absorbance of six replicates (0.01 μg 
/mL) for Method A and E, (0.045µg/mL) for Method B and F,  
(0.050µg/mL) for Method C and G, (0.065µg/mL) for Method 
D and H were noted and the % RSD was calculated. 
Accuracy was evaluated as per the ICH guidelines by the 
percent recovery studies by the addition of 50%, 100%, and 
150% of Osimertinib Mesylate solution extracted from the 
formulation was taken and the % RSD was calculated.  
3. RESULTS  
New spectrophotometric methods were developed for the 
determination of Osimertinib Mesylate in pharmaceutical 
preparations. Osimertinib Mesylate has shown absorption 
maxima (λmax) at 214 nm in 0.1N HCl (Method A) and Sodium 
acetate buffer pH 4.5 (Method B) and phosphate buffer pH 
7.2 (Method C) and methanol (Method D) the corresponding 
absorption spectra were shown in Figures, 
 
 
Figure 2: Absorption spectrum of Osimertinib Mesylate 
(1.0 µg /mL) in 0.1N HCl 
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Figure 3: Absorption spectrum of Osimertinib Mesylate 
(1.0 µg /mL) in pH 4.5 Acetate Buffer 
 
Figure 4: Absorption spectrum of Osimertinib Mesylate 
(1.0 µg /mL) in pH 7.2 Phosphate Buffer 
 
Figure 5: Absorption spectrum of Osimertinib Mesylate 
(1.0 µg /mL) in Methanol 
In method E, Osimertinib Mesylate has shown zero crossing 
points at 241.55, 267.36, and 373.41 nm, with maxima at 
255.21 nm and minima at 283.19 nm in Figure 6 and 
therefore the amplitude has been taken against the 
concentration for the construction of the calibration curve. 
Similarly, in method F, Osimertinib Mesylate has shown zero 
crossing point at 242.47, 265.09, 298.07 and 334.69 with 
maxima at 252.18 nm and minima at 276.86 nm in Figure 7 
and therefore the amplitude has been taken against the 
concentration for the construction of the calibration curve. 
Similarly, in method G, Osimertinib Mesylate has shown zero 
crossing point at 201.95, 212.06, 242.50, 265.07, 297.52, 
334.28, 334.71 and 335.00 with maxima at 252.19 nm and 
minima at 276.80 nm in Figure 8 and therefore the 
amplitude has been taken against the concentration for the 
construction of the calibration curve. Similarly, in method H, 
Osimertinib Mesylate has shown zero crossing point at 
202.74, 246.05, 266.69, 295.51 and 316.98with maxima at 
257.60 nm and minima at 282.92 nm in Figure 9 and 
therefore the amplitude has been taken against the 
concentration for the construction of the calibration curve 
 
Figure 6: Overlay first derivative spectra (D1) of 
Osimertinib Mesylate in 0.1N HCl 
 
Figure 7: Overlay first derivative spectra (D1) of 
Osimertinib Mesylate in pH 4.5 Acetate buffer 
 
Figure 8: Overlay first derivative spectra (D1) of 
Osimertinib Mesylate in pH 7.2 phosphate Buffer 
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Figure 9: Overlay first derivative spectra (D1) of 
Osimertinib Mesylate in methanol 
Beer’s law was obeyed in the concentration range of 0.002-
0.02 µg / mL for method A and E and 0.002-0.02 µg/mL for 
Method B and F and 0.002-0.02 µg/mL for Method C and G 
and 0.002-0.02 µg/mL for Method D and H.  The linear 
regression equations were found to be y = 0.4323x + 0.0104, 
y = 0.0259x + 0.0008, y = 0.484x - 0.017, y = 0.0137x - 
0.0005, y=0.2949x+0.0108, y=0.0097x-0.0008, y=0.6323x+ 
0.003 and y=0.0087x-0.0007 for method A, B, C, D, E, F, G and 
H respectively (Figure 6) with correlation coefficient 0.9994, 
0.9991, 0.9993, 0.9994, 0.9992, 0.9992, 0.9992 and 0.999 
respectively (Table 1).  
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Figure 10: Calibration curves of Osimertinib Mesylate in method A, B, C, D, E, F, G and H
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Table 1: Optical characteristics of Osimertinib Mesylate 
Parameters 
Method 
A B C D E F G H 
Beer-Lambert’s limits (µg /mL) 0.002-0.02 
0.002-
0.02 
0.002-
0.02 
0.002-
0.02 
0.002-
0.02 
0.002-
0.02 
0.002-
0.02 
0.002-
0.02 
λmax/Amplitude range (nm) 267 267 267 267 
255.30-
283.30 
252.34- 
276.88 
252.01- 
276.80 
257.66- 
282.91 
Regression equation 
0.4323x+ 
0.0104 
0.484x-
0.017 
0.2949x+ 
0.0108 
0.6323x+ 
0.003 
0.0259x+ 
0.0008 
0.0137x- 
0.0005 
0.0097x-
0.0008 
0.0087x-
0.0007 
Slope 0.4323 0.484 0.2949 0.6323 0.0259 0.0137 0.0097 0.0087 
Intercept 0.0104 0.017 0.003 0.003 0.0008 0.0005 0.0008 0.0007 
Correlation coefficient 0.9992 0.9992 0.9992 0.999 0.9994 0.9991 0.9993 0.9994 
Sandells Sensitivity 
2.49* 
10-5 µgcm-
2 
1.97* 
10-5 
µgcm-2 
3.28* 
10-5µgcm-
2 
1.00* 
10-5 
µgcm-2 
4.52* 
10-4 
µgcm-2 
7.09* 
10-4 
µgcm-2 
1.19* 
10-4 
µgcm-2 
3.57* 
10-4 
µgcm-2 
                                                                
The % RSD values in precision studies were found to be 0.12, 
0.28, 0.34, 0.24, 0.57, 0.69 and 0.91 for method  A, B, C and D 
respectively (RSD <2%) indicating that the method is more 
precise. The % Recovery values (Table 2)  were found  to be 
99.10%, 99.23%, 99.34%, 99.44%, 99.32%, 99.12%, 99.47% 
and 99.50% with RSD 0.13, 0.39, 0.45, 0.56, 0.35, 0.68 and 
0.74 for method A, B, C and D respectively (RSD <2%) 
indicating that the proposed methods can be applied for the 
determination of pharmaceutical formulations and the 
method is more accurate.  
LOQ is defined as the lowest amount of analyte which can be 
detected. LOD was defined as the lowest amount of analyte 
which can be quantitatively determined. LOD and LOQ of the 
drug were calculated as per ICH guidelines. The Limit of 
Detection and Limit of Quantification was found to be 
0.25µg/ml and 0.825µg/ml (Method A and E) and 0.6µg/mL 
and 1.98µg/mL (Method B and F) and 0.2µg/ml and 
0.66µg/ml (Method C and G) and 0.3µg/ml and 0.99µg/ml 
(Method D and H) respectively. 
 
Table 2: Assay of API 
 
Level 
*Amount obtained (mg) 
Method 
A B C D E F G H 
50 0.4939 0.4944 0.4955 0.4964 0.4957 0.4954 0.4966 0.4943 
100 0.9949 0.9910 0.9961 0.9972 0.9932 0.9940 0.9953 0.9964 
150 0.9965 0.9930 0.9979 0.9986 0.9951 0.9979 0.9961 0.9975 
  
Table 3: Assay of API 
 
Level 
% Recovery* 
Method 
A B C D E F G H 
50   99.10 99.23 99.34 99.44 99.32 99.12 99.47 99.50 
100 99.41 99.12 99.51 99.64 99.31 99.40 99.61 99.71 
150 99.61 99.20 99.62 99.71 99.59 99.50 99.79 99.80 
 
 
DISCUSSION 
The objective of the analytical procedure is to govern the 
validation characteristics which need to be evaluated. 
Typical validation characteristics which should be 
considered are listed below: Linearity, Accuracy, Precision, 
LOD, and LOQ. The linear regression data for the calibration 
plot were indicative of a good linear relationship between 
peak area and concentration over a wide range. The results 
have shown best recoveries (98-102%) of the spiked drug at 
each added concentration, indicating that the method was 
accurate. The precision of Osimertinib Mesylate was 
evaluated and the percentage relative standard deviation 
(%RSD) was found to be less than 2% which proves that the 
method was precise. And the Limit of Detection and Limit of 
Quantification was found to be 0.25µg/ml and 0.825µg/ml 
(Method A and E) and 0.6µg/mL and 1.98µg/mL (Method B 
and F) and 0.2µg/ml and 0.66µg/ml (Method C and G) and 
0.3µg/ml and 0.99µg/ml (Method D and H) respectively. 
Hence the proposed method was sensitive. 
CONCLUSION 
The present methods can be employed for the determination 
of Osimertinib Mesylate in pharmaceutical formulations 
successfully and there is no interference of excipients during 
the study.   
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